Sign Up to like & get
recommendations!
1
Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.841
Abstract: Fixed‐dose combination (FDC) drugs with various dose combinations for the treatment of type 2 diabetes mellitus and dyslipidemia are currently in demand. We compared the pharmacokinetic (PK) profiles of the rosuvastatin/metformin sustained‐release (10/1000 mg) FDC…
read more here.
Keywords:
rosuvastatin metformin;
metformin;
sustained release;
metformin sustained ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2017.07.038
Abstract: PURPOSE Rosuvastatin and ezetimibe are concomitantly used for dyslipidemia treatment. Compared with separate tablets, fixed-dose combination (FDC) tablets of rosuvastatin/ezetimibe could increase patient compliance. The aim of this study was to compare the pharmacokinetic (PK)…
read more here.
Keywords:
rosuvastatin ezetimibe;
dose combination;
rosuvastatin;
study ... See more keywords